This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
Yes
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Risk is elevated in crowded settings and developing countries. Recommended for travelers over 65, those with chronic conditions, and asplenic individuals.
Serious bacterial infections caused by Streptococcus pneumoniae (pneumococcus), ranging from ear infections to life-threatening pneumonia, meningitis, and sepsis.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| High fever | 90% | Severe | Early |
| Chills | 80% | Moderate | Early |
| Productive cough | 75% | Moderate | Early |
| Shortness of breath | 70% | Moderate | Early |
| Neck stiffness | 40% | Severe | Peak |
| Severe headache | 50% | Severe | Peak |
| Confusion | 30% | Severe | Peak |
| Hypotension | 15% | Severe | Peak |
| Photophobia | 25% | Moderate | Peak |
| Seizures | 20% | Severe | Peak |
Pneumococcal disease is a group of illnesses caused by the bacterium Streptococcus pneumoniae (the pneumococcus), a Gram-positive, lancet-shaped, facultatively anaerobic diplococcus. Over 100 serotypes have been identified based on the polysaccharide composition of the bacterial capsule, which is the primary virulence factor and the basis for vaccine development.
S. pneumoniae is a common commensal of the human nasopharynx, with carriage rates of 20–40% in children and 5–10% in adults in non-epidemic settings. Carriage is typically asymptomatic and transient (lasting weeks to months), but serves as the reservoir for both disease and person-to-person transmission via respiratory droplets.
The clinical spectrum of pneumococcal disease ranges from common non-invasive mucosal infections to life-threatening invasive disease. Non-invasive pneumococcal disease includes community-acquired pneumonia (without bacteremia), acute otitis media, and sinusitis. Invasive pneumococcal disease (IPD) is defined by isolation of S. pneumoniae from a normally sterile body site (blood, cerebrospinal fluid, pleural fluid, joint fluid) and includes bacteremic pneumonia, meningitis, empyema, peritonitis, and septic arthritis.
Pneumococcal disease remains a leading cause of vaccine-preventable death worldwide. The WHO estimates approximately 1.2 million deaths annually, including an estimated 300,000–500,000 deaths in children under 5 years, predominantly in low- and middle-income countries. The introduction of pneumococcal conjugate vaccines (PCVs) into national immunization programs has substantially reduced IPD incidence in high-income countries but global coverage remains incomplete.
Streptococcus pneumoniae is the most common bacterial cause of community-acquired pneumonia in adults and a major cause of meningitis, bacteremia, and otitis media across all age groups. The disease burden follows a bimodal age distribution, disproportionately affecting children under 2 years and adults over 65 years.
The spectrum of clinical disease is determined by the interaction between bacterial virulence factors (capsular serotype, surface proteins, pneumolysin) and host immune defenses. Certain serotypes (1, 3, 5, 7F, 14, 19A, 19F, 23F) are more commonly associated with invasive disease. Serotype 3 remains a significant cause of IPD and is associated with particularly poor outcomes including empyema.
Antimicrobial resistance is an escalating concern. Globally, 30–40% of pneumococcal isolates are penicillin-nonsusceptible in some regions, and multidrug resistance (to 3 or more drug classes) is increasing. Macrolide resistance exceeds 50% in parts of Asia. This resistance trend underscores the importance of vaccination as a primary prevention strategy.
Two categories of pneumococcal vaccines are available: pneumococcal conjugate vaccines (PCVs) — PCV13, PCV15, and PCV20 — which elicit T-cell-dependent immune responses and are effective in young children, and pneumococcal polysaccharide vaccine (PPSV23), which covers 23 serotypes but generates T-cell-independent responses inadequate for children under 2 years. The WHO recommends PCV for all infants as part of routine immunization schedules, with coverage reaching approximately 60% globally.
Pneumococcal disease can progress rapidly from mild symptoms to life-threatening illness. Seek emergency medical attention immediately for the following:
Signs of meningitis (medical emergency):
Severe headache with neck stiffness or inability to flex the chin to the chest
High fever with altered mental status, confusion, or drowsiness
Photophobia (severe sensitivity to light)
Non-blanching petechial or purpuric rash (may indicate associated septicemia)
Seizures, particularly in the context of fever
Bulging fontanelle in infants, with or without fever
Signs of severe pneumonia or sepsis:
Respiratory rate >30 breaths/minute in adults
Oxygen saturation <92% or cyanosis
Systolic blood pressure <90 mmHg or signs of circulatory shock (cold extremities, weak pulse, prolonged capillary refill)
Confusion or new-onset altered mental status (CURB-65 score ≥3)
Bilateral or multilobar involvement on presentation
Temperature >40°C or hypothermia (<35°C)
In children:
Rapid or labored breathing with chest indrawing (subcostal, intercostal, or suprasternal retractions)
Inability to drink or breastfeed
Lethargy, reduced consciousness, or inconsolable crying
Convulsions
Pneumococcal meningitis has a case fatality rate of 20–30% even with optimal treatment, and permanent neurological sequelae (hearing loss, cognitive impairment) occur in 25–50% of survivors. Every hour of delay in antibiotic administration for meningitis increases mortality. If meningitis is suspected, empiric antibiotics should be administered immediately, even before neuroimaging or lumbar puncture if these would cause delay.
Most common signs and symptoms
The clinical presentation of pneumococcal disease varies according to the site of infection and the patient's age and immune status.
Pneumococcal pneumonia is the most common clinical manifestation. Classic presentation includes abrupt onset of fever with rigors, productive cough with rusty or purulent sputum, pleuritic chest pain, dyspnea, and tachypnea. Physical examination reveals signs of consolidation: bronchial breath sounds, dullness to percussion, egophony, and increased tactile fremitus. In elderly patients, pneumonia may present atypically with confusion, falls, hypothermia, or absence of fever, leading to delayed diagnosis.
Pneumococcal meningitis presents with the classic triad of fever, neck stiffness, and altered mental status, though all three are present simultaneously in only 40–50% of cases. Headache is severe and generalized. Photophobia, nausea, and vomiting are common. The onset is typically acute (hours to 1–2 days). Kernig and Brudzinski signs may be present. Seizures occur in approximately 15–30% of cases, and cranial nerve palsies (particularly III, VI, and VIII) may develop.
Pneumococcal bacteremia without a focus occurs primarily in young children (6 months to 3 years) and presents with high fever (≥39°C), irritability, and often no localizing signs. This occult bacteremia carries a risk of progression to meningitis (approximately 3–6% if untreated) or other metastatic foci.
Acute otitis media (AOM) is the most frequent pneumococcal infection in children, presenting with ear pain, fever, irritability, and bulging or erythematous tympanic membrane. Pneumococcus causes approximately 30–40% of AOM episodes and tends to cause more severe disease than other bacterial pathogens.
Knowing the symptoms is the first step to a quick response.
The clinical course of pneumococcal disease varies by syndrome, ranging from the acute onset of meningitis to the more indolent course of otitis media. The incubation period is typically 1–3 days from mucosal acquisition to invasive disease, though the bacterium may colonize the nasopharynx asymptomatically for weeks to months before causing clinical illness.
Pneumococcal pneumonia typically follows a preceding viral upper respiratory infection that disrupts mucociliary clearance, allowing pneumococci to reach the lower airways. Onset is characteristically abrupt, with rigor-associated fever appearing within hours, followed by productive cough and pleuritic chest pain. Without treatment, the "crisis" — abrupt defervescence occurring on days 5–7 — was historically observed and associated with effective immune clearance. With appropriate antibiotic therapy, fever typically resolves within 48–72 hours; persistent fever beyond 72 hours suggests complications (empyema, abscess) or treatment failure.
Pneumococcal meningitis follows an even more fulminant course. Initial symptoms of headache and fever may progress within hours to meningeal signs, altered consciousness, and seizures. The course is characterized by rapid clinical deterioration. Without treatment, death occurs within days. Even with optimal antibiotic therapy, clinical improvement may take 48–72 hours, and complications (cerebral edema, hydrocephalus, vasculitis, hearing loss) often develop within the first 48 hours.
Pneumococcal bacteremia in young children may initially present subtly as occult bacteremia with high fever alone. Without treatment, this may resolve spontaneously in 70–90% of cases, but approximately 3–6% develop meningitis and a smaller proportion develop other focal infections.
Recovery timeline: For uncomplicated pneumonia, most patients show significant improvement by days 3–5 of antibiotics, with radiographic resolution lagging behind clinical improvement by 4–8 weeks (longer in elderly and those with COPD). For meningitis, hospital stays average 14–21 days, with rehabilitation potentially extending for months.
How this disease is identified
Definitive diagnosis of pneumococcal disease requires isolation or detection of Streptococcus pneumoniae from clinical specimens. The diagnostic approach varies by clinical syndrome.
Blood culture is the reference standard for diagnosing pneumococcal bacteremia and should be obtained in all patients with suspected invasive pneumococcal disease before antibiotic administration. Sensitivity for pneumococcal pneumonia is approximately 25–30% (as only a minority of pneumonia cases are bacteremic), but a positive blood culture confirms the etiology and provides isolates for susceptibility testing.
Urinary antigen testing for pneumococcal C-polysaccharide (e.g., BinaxNOW S. pneumoniae) provides rapid results within 15 minutes with a sensitivity of 70–80% and specificity of approximately 90% for bacteremic pneumococcal pneumonia. The test may remain positive for weeks after acute infection and may yield false positives in children with nasopharyngeal colonization. It is particularly useful as it is not affected by prior antibiotic therapy.
Cerebrospinal fluid (CSF) analysis is essential for diagnosing pneumococcal meningitis. Classic findings include elevated opening pressure (>200 mm H₂O), pleocytosis (typically 1,000–5,000 WBC/μL, predominantly neutrophils), elevated protein (>100 mg/dL), and markedly decreased glucose (<40 mg/dL or CSF:serum glucose ratio <0.4). Gram stain shows Gram-positive diplococci in 60–80% of cases. CSF culture is positive in 80–90% of untreated cases but sensitivity drops significantly after antibiotic exposure.
Molecular diagnostics are increasingly important, particularly when cultures are negative due to prior antibiotics. PCR for pneumococcal DNA (targeting lytA or ply genes) in blood and CSF offers sensitivity of 90–100% and rapid results. Multiplex PCR panels for meningitis/encephalitis simultaneously detect S. pneumoniae and other common pathogens.
Sputum Gram stain and culture for pneumonia have variable utility: a quality specimen (>25 WBC, <10 epithelial cells per low-power field) showing Gram-positive diplococci supports the diagnosis, but sensitivity is only 50–60% and is affected by prior antibiotic use.
Available treatment methods
Treatment of pneumococcal disease requires prompt initiation of appropriate antibiotic therapy, with the choice of agent guided by the clinical syndrome, disease severity, local resistance patterns, and susceptibility testing.
Pneumococcal pneumonia:
Outpatient (mild-moderate): Amoxicillin (first-line for penicillin-susceptible strains), or a respiratory fluoroquinolone (levofloxacin, moxifloxacin) for penicillin-allergic patients. Macrolides (azithromycin, clarithromycin) as monotherapy only where local macrolide resistance is <25%.
Inpatient (non-ICU): Beta-lactam (ceftriaxone, cefotaxime, or ampicillin-sulbactam) plus a macrolide, or a respiratory fluoroquinolone alone.
ICU (severe): Beta-lactam (ceftriaxone or ampicillin-sulbactam) plus a macrolide or a respiratory fluoroquinolone. For Pseudomonas risk, piperacillin-tazobactam or meropenem.
Pneumococcal meningitis:
Empiric therapy: Ceftriaxone (2g IV every 12 hours) plus vancomycin (15–20 mg/kg IV every 8–12 hours) is standard empiric treatment to cover potentially penicillin- and cephalosporin-resistant strains. Dexamethasone (0.15 mg/kg IV every 6 hours for 4 days) should be administered before or with the first dose of antibiotics — shown to reduce mortality (from 34% to 14%) and neurological sequelae in adults with pneumococcal meningitis.
De-escalation: Once susceptibility results are available, de-escalation to penicillin G (for MIC ≤0.06 μg/mL) or ceftriaxone alone (for MIC ≤0.5 μg/mL) is recommended. Duration: 10–14 days.
Antimicrobial resistance considerations: Penicillin resistance in pneumococcus is mediated by altered penicillin-binding proteins (not beta-lactamases), so beta-lactamase inhibitors offer no additional benefit. For meningitis, the MIC breakpoints are lower than for non-meningeal infections, meaning isolates considered "susceptible" for pneumonia may be "resistant" for meningitis treatment.
Supportive care includes oxygen therapy, intravenous fluids, chest physiotherapy (pneumonia), seizure management and ICP monitoring (meningitis), and management of complications such as empyema (chest tube drainage) and brain abscess.
Most cases are effectively treated with early diagnosis.
How to protect yourself
Prevention of pneumococcal disease centers on vaccination, which has transformed the epidemiology of IPD since the introduction of conjugate vaccines in 2000.
Pneumococcal conjugate vaccines (PCVs) are the cornerstone of prevention, particularly for young children:
PCV13 (Prevnar 13): Covers serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F. Standard infant schedule: 3 primary doses + 1 booster (3+1) or 2+1 depending on country guidelines.
PCV15 (Vaxneuvance): Adds serotypes 22F and 33F to the PCV13 formulation.
PCV20 (Prevnar 20): Adds serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F to PCV13, covering approximately 85% of IPD serotypes in adults.
In adults, current recommendations include PCV20 alone (single dose) for all adults ≥65 years and for adults 19–64 years with risk factors for pneumococcal disease. Alternatively, PCV15 followed by PPSV23 (≥1 year later) provides broader serotype coverage, though the simpler PCV20 single-dose regimen is increasingly preferred.
PPSV23 (Pneumovax 23) covers 23 serotypes and is effective in adults but does not generate immunological memory or significantly reduce nasopharyngeal carriage. It is no longer recommended as a standalone first-line vaccine in most guidelines but may complement PCV15 in sequential regimens.
Indirect (herd) protection is a major benefit of childhood PCV programs. By reducing nasopharyngeal carriage of vaccine serotypes in children (the primary reservoir), PCVs reduce transmission to unvaccinated adults, resulting in 20–40% reductions in adult IPD even without direct adult vaccination.
Additional prevention measures include: management of underlying risk factors (smoking cessation, HIV treatment, optimization of chronic disease management), judicious antibiotic use to limit resistance, and prophylactic antibiotics for high-risk individuals (e.g., asplenic patients receiving daily penicillin V prophylaxis).
Preparation is the best protection.
Pneumococcal disease is globally distributed and not typically classified as a travel-specific infection. However, several considerations are relevant for international travelers:
Pre-travel vaccination assessment: Travelers with risk factors for pneumococcal disease should ensure they are up to date with pneumococcal vaccination before departure. This is particularly important for individuals with functional or anatomic asplenia (including sickle cell disease), HIV infection, immunosuppressive therapy, chronic cardiopulmonary disease, and adults ≥65 years. Splenectomized travelers face a lifelong risk of overwhelming pneumococcal sepsis and should carry emergency antibiotics (amoxicillin) for empiric treatment if they develop fever in areas with limited healthcare access.
Antimicrobial resistance patterns vary geographically. Penicillin nonsusceptibility rates are particularly high in parts of East Asia (40–60%), Eastern Europe, and sub-Saharan Africa. Macrolide resistance exceeds 70% in China and Vietnam. Travelers to regions with high resistance rates who develop pneumococcal symptoms may require broader-spectrum empiric therapy.
Crowded travel settings increase pneumococcal transmission risk. Pilgrimage (Hajj, Kumbh Mela), military deployment, refugee camps, and dormitory-style accommodation elevate exposure. Respiratory outbreaks in these settings may involve pneumococcal disease as a secondary bacterial infection following influenza or viral URI.
Altitude and air travel: Travelers to high-altitude destinations should be aware that altitude-related immune changes may modestly increase susceptibility to respiratory infections. Cabin air during long-haul flights is dry and recirculated, though HEPA filtration reduces pathogen transmission.
Healthcare access considerations: Travelers to remote areas or low-resource settings should be aware that definitive diagnostic testing (blood culture, CSF analysis) and appropriate antibiotics may not be immediately available. A low threshold for seeking medical evaluation for high fever, respiratory distress, or headache with neck stiffness is essential.
Statistics and geographic data
Pneumococcal disease is a major global health burden, with Streptococcus pneumoniae remaining the leading bacterial cause of pneumonia, meningitis, and bacteremia worldwide despite the availability of effective vaccines.
Global mortality: The WHO estimates approximately 1.2 million deaths attributable to pneumococcal disease annually, including an estimated 300,000–500,000 deaths in children under 5 years. Pneumococcal pneumonia alone causes an estimated 800,000 deaths in children under 5 annually, making it the single leading infectious cause of death in this age group. The vast majority of childhood pneumococcal deaths occur in sub-Saharan Africa and South-East Asia.
Invasive pneumococcal disease (IPD) incidence varies by region and population. In the pre-PCV era, IPD incidence in high-income countries was approximately 15–30/100,000 overall, with peaks in children under 2 years (50–100/100,000) and adults over 65 (25–60/100,000). Following introduction of PCV7 (2000) and PCV13 (2010), IPD rates in vaccine-eligible populations have declined by 60–90% for vaccine serotypes.
Serotype replacement is a recognized phenomenon following PCV introduction. As vaccine serotypes are suppressed, non-vaccine serotypes (e.g., 8, 12F, 22F, 33F, 15B) have expanded to fill the ecological niche, partially offsetting reductions in overall IPD. This serotype replacement has driven the development of expanded-valency vaccines (PCV15, PCV20) and next-generation common protein-based vaccines.
Antimicrobial resistance: Pneumococcal resistance is a WHO priority pathogen concern. Globally, penicillin nonsusceptibility (MIC ≥0.12 μg/mL by meningitis breakpoints) ranges from 10–60% depending on region and serotype. Multidrug-resistant (MDR) pneumococcus, resistant to ≥3 drug classes, is reported in 15–30% of isolates in some Asian and European countries. Serotype 19A has been particularly associated with MDR.
Seasonality: In temperate climates, IPD peaks during winter months (December–March in the Northern Hemisphere), correlating with respiratory virus season. This seasonality is attributed to increased viral co-infections, closer indoor contact, and environmental factors affecting mucosal integrity.
Who is most at risk
Risk factors for pneumococcal disease are well defined and form the basis for targeted vaccination and prevention strategies.
Age-related risk:
Children <2 years: Immature immune system, particularly poor polysaccharide antibody responses. Highest incidence of IPD (approximately 50–100/100,000 in the pre-vaccine era)
Adults ≥65 years: Immunosenescence, increased comorbidity burden. IPD incidence of 25–40/100,000 in unvaccinated populations
Immunocompromising conditions (highest risk, 20–100-fold increased):
HIV/AIDS: CD4 count <200 cells/μL confers the greatest risk; IPD rates 40-fold higher than HIV-negative adults
Functional or anatomic asplenia: Including sickle cell disease, splenectomy, splenic irradiation. Risk of overwhelming post-splenectomy infection (OPSI) with 50–70% mortality
Primary immunodeficiency: Complement deficiency, antibody deficiency syndromes
Organ transplantation: Solid organ and hematopoietic stem cell transplant recipients
Malignancy: Hematological malignancies (especially multiple myeloma, leukemia), cancer chemotherapy
Chronic corticosteroid therapy: ≥20 mg/day prednisone equivalent for ≥14 days
Chronic medical conditions (moderate risk, 3–10-fold increased):
Chronic lung disease: COPD, asthma, bronchiectasis, interstitial lung disease
Cardiovascular disease: Congestive heart failure, cardiomyopathy (not isolated hypertension)
Diabetes mellitus: Both type 1 and type 2, particularly if poorly controlled
Chronic liver disease: Cirrhosis, alcoholic liver disease
Chronic kidney disease: Especially nephrotic syndrome and end-stage renal disease
Cochlear implant recipients: Increased risk of pneumococcal meningitis
Behavioral and environmental risk factors:
Cigarette smoking: 2–4-fold increased risk of IPD; impairs mucociliary clearance and alveolar macrophage function
Alcohol misuse: Associated with aspiration, impaired immune function, and liver disease
Crowded living conditions: Dormitories, prisons, military barracks, long-term care facilities
Preceding viral respiratory infection: Influenza in particular predisposes to secondary pneumococcal pneumonia
Potential complications
Pneumococcal disease is associated with a wide range of complications, many of which carry significant morbidity and mortality. The risk and nature of complications depend on the site of primary infection, the patient's age, and underlying health status.
Complications of pneumococcal pneumonia:
Parapneumonic effusion and empyema: Pleural involvement occurs in 20–40% of hospitalized pneumococcal pneumonia cases. Simple parapneumonic effusions may resolve with antibiotics alone, but complicated effusions and empyema (frank pus in the pleural space) require chest tube drainage and may necessitate surgical decortication. Pneumococcal serotype 1 and 3 are particularly associated with empyema formation.
Lung abscess: Rare but serious, requiring prolonged antibiotic therapy (4–8 weeks) and occasionally percutaneous or surgical drainage.
Acute respiratory distress syndrome (ARDS): Severe pneumococcal pneumonia may trigger ARDS, requiring mechanical ventilation with a mortality rate of 30–50%.
Cardiovascular events: Acute myocardial infarction, new-onset arrhythmias (particularly atrial fibrillation), and decompensated heart failure occur in an estimated 10–30% of hospitalized pneumococcal pneumonia patients.
Complications of pneumococcal meningitis:
Hearing loss: Sensorineural hearing loss is the most common neurological sequela, occurring in 14–30% of survivors. It may be uni- or bilateral and can be progressive. Early audiological assessment is essential, and cochlear implantation may be considered for severe bilateral loss.
Cerebral edema and herniation: The leading cause of early death in pneumococcal meningitis, manifesting as deteriorating consciousness, posturing, and pupillary abnormalities.
Hydrocephalus: Both communicating and non-communicating forms may develop acutely or subacutely, requiring CSF diversion (external ventricular drain or ventriculoperitoneal shunt).
Cerebral infarction: Vasculitis-mediated ischemic stroke occurs in 15–25% of cases.
Subdural empyema and brain abscess: Rare but devastating complications requiring neurosurgical intervention.
Cognitive and behavioral sequelae: Long-term cognitive deficits, including impaired memory, concentration, and executive function, affect 30–50% of adult meningitis survivors.
Expected outcomes and recovery
The prognosis of pneumococcal disease varies dramatically depending on the clinical syndrome, patient age, comorbidities, and timeliness of treatment.
Pneumococcal pneumonia has an overall case fatality rate of approximately 5–7% in hospitalized patients in high-income countries, but this rises to 20–30% in patients with bacteremia and those requiring ICU admission. In outpatient-managed community-acquired pneumonia, mortality is less than 1%. Prognostic scores such as CURB-65 and PSI/PORT help stratify risk: patients with CURB-65 scores of 0–1 have <3% mortality, while scores ≥3 carry 15–40% mortality.
Pneumococcal meningitis carries the highest mortality among common bacterial meningitis pathogens, with a case fatality rate of 20–30% in high-income countries and up to 50–60% in resource-limited settings. Among survivors, 25–50% experience permanent neurological sequelae, including sensorineural hearing loss (the most common, affecting 14–30% of survivors), cognitive impairment, focal neurological deficits, seizure disorders, and hydrocephalus. Prognostic factors associated with poor outcomes include advanced age, low Glasgow Coma Scale score at presentation, high CSF bacterial load, and delay in antibiotic administration.
Invasive pneumococcal disease in children has improved dramatically since PCV introduction. Pre-PCV mortality in children under 5 was approximately 10–15% for IPD overall and 25–30% for meningitis; post-PCV, these figures have declined by 40–60% in countries with high vaccine coverage. However, serotype replacement with non-vaccine serotypes has partially offset these gains.
Long-term outcomes: Patients recovering from pneumococcal pneumonia have an elevated risk of cardiovascular events (myocardial infarction, heart failure) for up to 10 years after the acute episode. Meningitis survivors require long-term audiological follow-up and may need cognitive rehabilitation. Recurrent IPD should prompt evaluation for underlying immunodeficiency, particularly asplenia, complement deficiency, or HIV.
This disease is vaccine-preventable. Effective protection is available through vaccination.
Talk to a travel health specialist about the recommended schedule before your trip.
Find a vaccination clinic →The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useKnow which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.